Abstract:Aim/Background: BSA dosing leads to great inter-individual DTX PK variability, which is a major contributor for severe toxicity, especially in East-Asian populations. DTX exposure measured by area under plasma concentration-time curve (AUC) could positively predict DTX related neutropenia. We conducted a randomized clinical trial to assess the value of PK-guided DTX dosing on relieving toxicity.Methods: To date, 99 Asian advanced NSCLC patients were randomly assigned to receive single agent 3-weekly DTX chemotherapy for up to 6 cycles, either at a fixed standard dose of 75 mg/m2 by BSA (arm1) or at a PK-guided dose (arm2) with a same starting dose. AUC is calculated from a published PK model. Dose of subsequent cycles of arm2 patients is calculated base on previous cycle, according to optimal AUC target (2.5–3.7 µg•h/mL) algorithm. Dose reductions were permitted in both arms for toxicities. The study had a power of 80% to detect a 23% reduction of grade >3 neutropenia with PK-guided arm.Results: Patients' major characteristics were male (62.6%), non-smoker (58.6%), ECOG 0 (80.8%) and adenocarcinoma (74.7%). 1st cycle of dosing 75 mg/m2 for all patients show 11 folds of PK variability, with mean AUC of 4.53 (range 1.8-20.3, CV = 56%), only 29.2% were in the target. Major patients (59.4%) were over exposed to DTX, experienced 18.5% higher of grade ≥3 neutropenia incidence. PK-guided dosing strategy could significantly reduce the dose of DTX, with a reduction of 8.6 mg/m2 (64.4 vs. 73.0, p < 0.001) in 2nd to 6th cycles. Patients therefore experienced 25.4% lower of grade ≥3 neutropenia incidence in PK-guided dose arm (47.5% vs. 72.9%, p = 0.002). Overall response rate showed no differences between arm2 and arm1 (20.0% vs. 17.5%, p = 0.769), so is progression free survival (4.6 vs. 3.4 months, p = 0.567).Conclusions: Majority of East-Asian NSCLC patients were over-exposed to DTX at a dose of 75 mg/m2. PK-guided dosing strategy could reduce DTX related neutropenia without efficacy damage.Clinical trial identification: NCT01891123Disclosure: All authors have declared no conflicts of interest. Aim/Background: BSA dosing leads to great inter-individual DTX PK variability, which is a major contributor for severe toxicity, especially in East-Asian populations. DTX exposure measured by area under plasma concentration-time curve (AUC) could positively predict DTX related neutropenia. We conducted a randomized clinical trial to assess the value of PK-guided DTX dosing on relieving toxicity. Methods: To date, 99 Asian advanced NSCLC patients were randomly assigned to receive single agent 3-weekly DTX chemotherapy for up to 6 cycles, either at a fixed standard dose of 75 mg/m2 by BSA (arm1) or at a PK-guided dose (arm2) with a same starting dose. AUC is calculated from a published PK model. Dose of subsequent cycles of arm2 patients is calculated base on previous cycle, according to optimal AUC target (2.5–3.7 µg•h/mL) algorithm. Dose reductions were permitted in both arms for toxicities. The study had a power of 80% to detect a 23% reduction of grade >3 neutropenia with PK-guided arm. Results: Patients' major characteristics were male (62.6%), non-smoker (58.6%), ECOG 0 (80.8%) and adenocarcinoma (74.7%). 1st cycle of dosing 75 mg/m2 for all patients show 11 folds of PK variability, with mean AUC of 4.53 (range 1.8-20.3, CV = 56%), only 29.2% were in the target. Major patients (59.4%) were over exposed to DTX, experienced 18.5% higher of grade ≥3 neutropenia incidence. PK-guided dosing strategy could significantly reduce the dose of DTX, with a reduction of 8.6 mg/m2 (64.4 vs. 73.0, p < 0.001) in 2nd to 6th cycles. Patients therefore experienced 25.4% lower of grade ≥3 neutropenia incidence in PK-guided dose arm (47.5% vs. 72.9%, p = 0.002). Overall response rate showed no differences between arm2 and arm1 (20.0% vs. 17.5%, p = 0.769), so is progression free survival (4.6 vs. 3.4 months, p = 0.567). Conclusions: Majority of East-Asian NSCLC patients were over-exposed to DTX at a dose of 75 mg/m2. PK-guided dosing strategy could reduce DTX related neutropenia without efficacy damage. Clinical trial identification: NCT01891123 Disclosure: All authors have declared no conflicts of interest.

Paclitaxel (ptx) Dose Individualization by Exposure Optimization in Chinese Patients with Advanced Non Small-Cell Lung Cancer (nsclc) Receiving First-Line Paclitaxel-Carboplatin (pc) Chemotherapy.

Open-label Randomized Study of Individualized Pharmacokinetically (Pk)-Guided Dosing Versus Body Surface Area (BSA) Dosing of Paclitaxel (PTX) in Advanced Non-Small Cell Lung Cancer (NSCLC) NCT02058433

Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer.

424PD Individualization of docetaxel (DTX) treatment in East-Asian advanced non-small cell lung cancer (NSCLC) patients based on pharmacokinetically (PK)-guided dosing strategy: an open-label randomized clinical trial

Paclitaxel Exposure-Toxicity Analysis Reveals a Pharmacokinetic Determinant for Dose-Limiting Neutropenia in East-Asian Solid Tumor Patients: Results from Two Prospective, Phase II Studies

Outcome of Patients with a Performance Status of 2 in Eastern Cooperative Oncology Group Study E1594

TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients

Relationship between the key pharmacokinetic parameter Tc>0.05 and clinical toxicity in non-small cell lung cancer (NSCLC)patients receiving three-weekly paclitaxel

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Population Pharmacokinetics and Exposure–Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Paclitaxel combined with carboplatin in the treatment of elderly and younger patients with advanced non-small cell Lung cancer

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors

Optimal Exposure to Docetaxel in Adjuvant Chemotherapy for Early-Stage Breast Cancer.

Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer

Weekly Paclitaxel Improved Pathological Response of Primary Chemotherapy Compared with Standard 3 Weeks Schedule

Randomized Trial of Weekly Paclitaxel and Cisplatin Versus Paclitaxel and Cisplatin Every Three Weeks in the Treatment of Elderly Advanced NSCLC

Randomized Controlled Comparative Clinical Pharmacokinetic Study of Nab-Paclitaxel and Solvent-Based Paclitaxel in Chinese Patients (pts) with Metastatic Breast Cancer (MBC)